Guí a OncoSur de Cáncer de ovar io 38 > BIBLIOGRAFÍA 1. Redondo A, Guerra E, Manso L, Martín-Lorente C, Martínez-García J, Pérez-Fidalgo JA, et al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021;23(5):961-8. E-pub: 30 de enero de 2021. PMID: 33515422; PMCID: PMC8058000 2. Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, et al.; ESMO-ESGO Ovarian Cancer Consensus Conference Working Group. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. PMID: 31046081 3. Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2416-28. 4. Falandry C, Savoye AM, Stefani L, Tinquaut F, Lorusso D, Herrstedt J, et al. EWOC-1: a randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC) - A GCIG-ENGOT-GINECO study. J Clin Oncol. 2019;37(Suppl 15):5508. 5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34. 6. Walker J, Brady MF, DiSilvestro PA, Fujiwara K. A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG oncology study. Gynecol Oncol. 2016;141(1):208. 7. Walker JL. Long-term survival of GOG 252 randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/GOG Study. Phoenix, Arizona: 2022 SGO Annual Meeting on Women’s Cancer; 2022. 8. Vanderpuye VD, Clemenceau JRV, Temin S, Aziz Z, Burke WM, Cevallos NL, et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO Resource-Stratified Guideline. JCO Glob Oncol. 2021;7:1032-66. DOI: 10.1200/GO.21.00085. PMID: 34185571. PMCID: PMC8457806 9. Fujiwara K, Nagao S, Yamamoto K, Nagao S, Yoshikawa H, Sugiyama T, et al. A randomized phase 3 trial of intraperitoneal versus intravenous carboplatin with dose-dense weekly paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPoccTrial). Phoenix, Arizona: 2022 SGO Annual Meeting on Womens’ Cancer; 2022. 10. Lim MC, Chang SJ, Yoo HJ, Nam BH, Bristow R, Park SY. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol. 2017;35(Suppl 15):5520.
RkJQdWJsaXNoZXIy MTQzMjMwMg==